United States


VVUS.OQ on NASDAQ Stock Exchange Global Select Market

20 Sep 2017
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Select another date:

Tue, Sep 5 2017

BRIEF-VIVUS and Alvogen announce marketing agreement for Qsymia in the Republic of Korea

* VIVUS Inc - ‍Alvogen will be solely responsible for obtaining and maintaining regulatory approvals and for all sales and marketing activities in Korea​​

BRIEF-Dr.Reddy's Labs says overall impact on financials of settlement disputes with Vivus not likely to be material

* Dr.Reddy's Laboratories clarifies on news item regarding settling patent row with vivus

BRIEF-Vivus reports settlement with Dr. Reddy's laboratories on qsymia patent litigation

* Vivus announces settlement with Dr. Reddy's laboratories on qsymia(r) patent litigation

Vivus, Teva settle lawsuit over Teva's planned generic Qsymia

Vivus Inc has reached an agreement allowing Teva Pharmaceuticals Ltd to launch a generic version of its anti-obesity drug Qsymia by December 2024, settling a patent lawsuit Vivus brought in New Jersey federal court.

BRIEF-Vivus announces settlement with Actavis on Qsymia patent litigation

* Vivus announces settlement with actavis on qsymia(r) patent litigation

BRIEF-Vivus reports Q1 loss per share $0.01

* Total revenue, net for first quarters of 2017 and 2016, was $27.0 million and $15.3 million, respectively

BRIEF-Vivus reacquires Stendra(R)(AVANAFIL)commercial rights from Sanofi

* Reacquires Stendra(R) (Avanafil) commercial rights from Sanofi

Select another date: